Inventive Step Assessment For Biological Inventions

Introduction

Inventive step assessment for biological inventions refers to the legal examination of whether an invention involving biological materials, genetic engineering, microorganisms, plants, animals, pharmaceuticals or biotechnological processes contains a sufficient degree of technical advancement to qualify for patent protection.

An invention does not become patentable merely because it is new or involves scientific research. It must also demonstrate an inventive step, meaning that it must not be obvious to a person skilled in the relevant scientific or technical field.

Biological inventions create special challenges because many discoveries involve naturally occurring substances, genetic sequences, biological processes and living organisms. Patent authorities must distinguish between discovering something that already exists in nature and developing a genuinely inventive technological application.

Meaning Of Inventive Step

Inventive step is a fundamental requirement of patentability. It ensures that patents are granted only for inventions involving meaningful technical contributions rather than routine modifications or obvious developments.

Under Section 2(1)(ja) of the Indian Patents Act, 1970, an inventive step means a feature of an invention that involves a technical advance as compared with existing knowledge, or has economic significance, or both, and makes the invention non-obvious to a person skilled in the art.

For biological inventions, the assessment may consider:

Whether the invention introduces a new biological process or technique.

Whether it produces an unexpected technical result.

Whether the genetic modification involves more than routine experimentation.

Whether the invention improves efficiency, stability or functionality.

Whether the claimed biological material satisfies statutory patentability requirements.

Legal Framework In India

1. Patents Act, 1970

The Indian Patents Act establishes the legal framework for assessing inventive step in biological inventions.

Section 2(1)(ja) defines inventive step through technical advancement, economic significance and non-obviousness.

Section 3 contains important exclusions from patentability.

Section 3(c) excludes the mere discovery of a scientific principle or the discovery of any living thing or non-living substance occurring in nature.

Section 3(d) restricts patents for certain new forms of known substances unless they demonstrate enhanced efficacy as required by the provision.

Section 3(j) excludes plants and animals, in whole or in part, other than microorganisms, including seeds, varieties and species, and essentially biological processes for production or propagation of plants and animals.

These provisions are particularly important when examining inventions involving genes, microorganisms, genetically modified crops and biological materials.

2. Patent Rules and Examination Guidelines

The Patent Rules, 2003 provide procedural requirements for patent applications, examination and opposition.

The Indian Patent Office also follows examination guidance relating to biotechnology inventions. Patent examiners consider the description of biological materials, technical contribution, prior art and statutory exclusions.

An applicant must disclose the invention sufficiently to enable a person skilled in the art to perform it, subject to applicable patent-law requirements.

3. TRIPS Agreement, 1994

The Agreement on Trade-Related Aspects of Intellectual Property Rights establishes international minimum standards for patent protection.

Article 27 requires patents to be available for inventions, whether products or processes, in all fields of technology, subject to the Agreement's conditions.

However, Article 27(3)(b) permits members to exclude plants and animals other than microorganisms and essentially biological processes for producing plants or animals. It also requires protection of plant varieties through patents, an effective sui generis system or a combination of both.

India uses this flexibility through its exclusions under Section 3(j) and its plant-variety protection framework.

Criteria For Assessing Inventive Step In Biological Inventions

1. Identification Of Prior Art

The examiner first identifies existing scientific knowledge, patent publications, research papers and publicly available biological techniques.

For example, if a researcher develops a genetically modified microorganism, the examiner may compare the claimed genetic modification with previously disclosed microorganisms and established engineering methods.

2. Person Skilled In The Art

The invention is assessed from the perspective of a hypothetical person skilled in the relevant technical field.

In biotechnology, this person may possess knowledge of molecular biology, genetics, microbiology, genetic engineering or pharmaceutical development.

3. Technical Advancement

The applicant must demonstrate a meaningful technical contribution.

Examples may include improved biological stability, increased production efficiency, enhanced therapeutic performance or a technically improved method of producing a biological compound.

4. Non-Obviousness

An invention is not inventive if a skilled person could have arrived at it through ordinary technical knowledge and routine experimentation.

However, an unexpected technical result or a solution to a previously unresolved scientific problem may support an inventive-step claim.

5. Sufficient Disclosure

The patent specification must describe the invention clearly and adequately. Biological inventions may require detailed information about the biological material, genetic characteristics, experimental methods and reproducibility.

Important Case Laws

1. Biswanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979)

The Supreme Court of India explained that an invention must involve a real inventive contribution and must not be obvious to a person skilled in the relevant field.

The judgment remains important for determining inventive step under Indian patent law. Its principles apply to biological inventions because routine modifications of known biological techniques should not automatically receive patent protection.

2. Novartis AG v. Union of India (2013)

The Supreme Court examined the patentability of a modified form of an existing pharmaceutical substance under Section 3(d).

The Court emphasised that a new form of a known substance must satisfy the statutory requirement of enhanced therapeutic efficacy.

Although the case primarily concerned pharmaceutical patentability rather than inventive step alone, it is highly relevant to biotechnology because it demonstrates that technical modifications must satisfy India's substantive patentability requirements.

3. Dimminaco A.G. v. Controller of Patents and Designs (2002)

The Calcutta High Court considered a patent application involving a process for preparing a live vaccine.

The Court held that a process did not become unpatentable merely because its final product contained a living organism.

The judgment is significant for biological inventions because it recognised that certain biotechnology processes may qualify for patent protection, provided they satisfy the applicable patentability requirements.

4. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019)

The Supreme Court considered a dispute involving genetically modified cotton technology and patent rights.

The litigation raised questions concerning the relationship between patent protection, genetic modification and plant-variety legislation. The Court set aside the High Court's decision and remanded the matter for further consideration.

The case illustrates the complexity of patent claims involving biological materials and agricultural biotechnology.

5. Enercon (India) Ltd. v. Aloys Wobben (2014)

The Supreme Court considered issues relating to patent opposition and revocation procedures.

Although the dispute was not specifically about biological inventions, it is relevant to patent examination because it demonstrates the importance of procedural safeguards and scrutiny of patent validity.

International Judicial Developments

In Harvard College v. Canada (Commissioner of Patents) (2002), the Supreme Court of Canada considered whether a genetically modified mouse could be patented under Canadian law. The decision demonstrated that patent eligibility of higher life forms may differ across jurisdictions.

In Association for Molecular Pathology v. Myriad Genetics, Inc. (2013), the United States Supreme Court held that naturally occurring DNA is not patentable merely because it has been isolated. However, synthetically created complementary DNA may be patentable in appropriate circumstances. This distinction is important when assessing biological discoveries and technical inventions.

Challenges In Assessment

Inventive-step assessment in biotechnology involves several difficulties:

Rapid scientific developments can make prior-art searches complicated.

Biological experiments may produce unpredictable results.

The distinction between natural discovery and human-made invention can be difficult.

Routine genetic modifications may be presented as inventive developments.

Different jurisdictions may apply different standards to biological materials.

Inadequate disclosure can make biological inventions difficult to reproduce.

Patent examiners must therefore combine legal analysis with specialised scientific expertise.

Conclusion

Inventive step assessment for biological inventions ensures that patent protection is granted only to genuine technological contributions rather than discoveries of naturally occurring biological materials or routine scientific modifications.

In India, Section 2(1)(ja) of the Patents Act, 1970 provides the principal standard for assessing inventive step, while Sections 3(c), 3(d) and 3(j) establish important restrictions concerning biological inventions.

Judicial decisions such as Biswanath Prasad Radhey Shyam, Novartis, Dimminaco and Monsanto Technology demonstrate the importance of technical advancement, non-obviousness and statutory patentability requirements. A balanced approach protects genuine biotechnology innovation while preventing unjustified monopolisation of natural biological resources and basic scientific discoveries.